Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative

Six months after the publication of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) sequence, a record number of vaccine candidates were listed, and quite a number of them have since been approved for emergency use against the novel coronavirus disease 2019 (COVID-19). This unpreced...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Isaac Kyei-Barffour, Samuel Akwetey Addo, Enoch Aninagyei, George Ghartey-Kwansah, Desmond Omane Acheampong
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Sterilizing immunity Adaptive immune response COVID-19 SARS-CoV-2 Antigen Reverse vaccinology Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/bf7b697a21b34619b8042c67ff89a092
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bf7b697a21b34619b8042c67ff89a092
record_format	dspace
spelling	oai:doaj.org-article:bf7b697a21b34619b8042c67ff89a0922021-11-14T04:29:12ZSterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative0753-332210.1016/j.biopha.2021.112282https://doaj.org/article/bf7b697a21b34619b8042c67ff89a0922021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0753332221010660https://doaj.org/toc/0753-3322Six months after the publication of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) sequence, a record number of vaccine candidates were listed, and quite a number of them have since been approved for emergency use against the novel coronavirus disease 2019 (COVID-19). This unprecedented pharmaceutical feat did not only show commitment, creativity and collaboration of the scientific community, but also provided a swift solution that prevented global healthcare system breakdown. Notwithstanding, the available data show that most of the approved COVID-19 vaccines protect only a proportion of recipients against severe disease but do not prevent clinical manifestation of COVID-19. There is therefore the need to probe further to establish whether these vaccines can induce sterilizing immunity, otherwise, COVID-19 vaccination would have to become a regular phenomenon. The emergence of SARS-CoV-2 variants could further affect the capability of the available COVID-19 vaccines to prevent infection and protect recipients from a severe form of the disease. These notwithstanding, data about which vaccine(s), if any, can confer sterilizing immunity are unavailable. Here, we discuss the immune responses to viral infection with emphasis on COVID-19, and the specific adaptive immune response to SARS-CoV-2 and how it can be harnessed to develop COVID-19 vaccines capable of conferring sterilizing immunity. We further propose factors that could be considered in the development of COVID-19 vaccines capable of stimulating sterilizing immunity. Also, an old, but effective vaccine development technology that can be applied in the development of COVID-19 vaccines with sterilizing immunity potential is reviewed.Isaac Kyei-BarffourSamuel Akwetey AddoEnoch AninagyeiGeorge Ghartey-KwansahDesmond Omane AcheampongElsevierarticleSterilizing immunityAdaptive immune responseCOVID-19SARS-CoV-2AntigenReverse vaccinologyTherapeutics. PharmacologyRM1-950ENBiomedicine & Pharmacotherapy, Vol 144, Iss , Pp 112282- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Sterilizing immunity Adaptive immune response COVID-19 SARS-CoV-2 Antigen Reverse vaccinology Therapeutics. Pharmacology RM1-950
spellingShingle	Sterilizing immunity Adaptive immune response COVID-19 SARS-CoV-2 Antigen Reverse vaccinology Therapeutics. Pharmacology RM1-950 Isaac Kyei-Barffour Samuel Akwetey Addo Enoch Aninagyei George Ghartey-Kwansah Desmond Omane Acheampong Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative
description	Six months after the publication of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) sequence, a record number of vaccine candidates were listed, and quite a number of them have since been approved for emergency use against the novel coronavirus disease 2019 (COVID-19). This unprecedented pharmaceutical feat did not only show commitment, creativity and collaboration of the scientific community, but also provided a swift solution that prevented global healthcare system breakdown. Notwithstanding, the available data show that most of the approved COVID-19 vaccines protect only a proportion of recipients against severe disease but do not prevent clinical manifestation of COVID-19. There is therefore the need to probe further to establish whether these vaccines can induce sterilizing immunity, otherwise, COVID-19 vaccination would have to become a regular phenomenon. The emergence of SARS-CoV-2 variants could further affect the capability of the available COVID-19 vaccines to prevent infection and protect recipients from a severe form of the disease. These notwithstanding, data about which vaccine(s), if any, can confer sterilizing immunity are unavailable. Here, we discuss the immune responses to viral infection with emphasis on COVID-19, and the specific adaptive immune response to SARS-CoV-2 and how it can be harnessed to develop COVID-19 vaccines capable of conferring sterilizing immunity. We further propose factors that could be considered in the development of COVID-19 vaccines capable of stimulating sterilizing immunity. Also, an old, but effective vaccine development technology that can be applied in the development of COVID-19 vaccines with sterilizing immunity potential is reviewed.
format	article
author	Isaac Kyei-Barffour Samuel Akwetey Addo Enoch Aninagyei George Ghartey-Kwansah Desmond Omane Acheampong
author_facet	Isaac Kyei-Barffour Samuel Akwetey Addo Enoch Aninagyei George Ghartey-Kwansah Desmond Omane Acheampong
author_sort	Isaac Kyei-Barffour
title	Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative
title_short	Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative
title_full	Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative
title_fullStr	Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative
title_full_unstemmed	Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative
title_sort	sterilizing immunity against covid-19: developing helper t cells i and ii activating vaccines is imperative
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/bf7b697a21b34619b8042c67ff89a092
work_keys_str_mv	AT isaackyeibarffour sterilizingimmunityagainstcovid19developinghelpertcellsiandiiactivatingvaccinesisimperative AT samuelakweteyaddo sterilizingimmunityagainstcovid19developinghelpertcellsiandiiactivatingvaccinesisimperative AT enochaninagyei sterilizingimmunityagainstcovid19developinghelpertcellsiandiiactivatingvaccinesisimperative AT georgegharteykwansah sterilizingimmunityagainstcovid19developinghelpertcellsiandiiactivatingvaccinesisimperative AT desmondomaneacheampong sterilizingimmunityagainstcovid19developinghelpertcellsiandiiactivatingvaccinesisimperative
_version_	1718430039511400448

Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative

Ejemplares similares